# Novel Magnesium Bioresorbable Scaffold New Insights on Next BRS Technology

### Preclinical evaluation of drug-eluting bioabsorbable magnesium scaffolds in a porcine coronary artery model

### Gaku Nakazawa<sup>1</sup>

Sho Torii<sup>2</sup>, Akiko Yamamoto<sup>3</sup>, Ayako Yoshikawa<sup>2</sup>

### 1. Department of Cardiology, Faculty of Medicine, Kindai University, Osaka, Japan

- 2. Department of Cardiology, School of Medicine, Tokai University, Kanagawa, Japan
- 3. Research Center for Functional Materials, National Institute for Material's Science





### Presenter: Gaku NAKAZAWA

Research fund: Japan Medical Device Technology Co., Ltd. Boston Scientific, Abbott Medical, Terumo Corp.


Honorarium : Boston Scientific, Abbott Medical, Terumo Corp., Daiichi-Sankyo, HeartFlow Japan.

This study is funded by Japan Medical Device Technology Co., Ltd.




### Late Stent Thrmobosis – Incomplete Healing is the Major Cause

#### Delayed Healing




Joner M & Finn AV. J Am Coll Cardiol. 2006;48(1):193-202.

#### Hypersensitivity



Nakazawa, G et al. J Am Coll Cardiol 2011:57(4).390-8

#### Neoatherosclerosis




Nakazawa, G & Otsuka, F et al. J Am Coll Cardiol. 2011:57(11):1314-22.





### **Greater Healing of 2nd Gen DES**






Otsuka F et al. Circulation. 2014;129:211-223



### Incidence of Neoatherosclerosis (> 5yrs)



#### **TCTAP2024**

Hiroyoshi Mori et al. J Am Heart Assoc 2017;6:e007244



Vascular factor

Endothelial dysfunction

Vulnerability of neointima

Chronic inflammation

### **Neoatherosclerosis**

Mechanical factor

Pulsatility


Conformability

Patient factor

Dyslipidemia

Acute coronary synd

# Absorbable devices were expected to solve the mechanical issues




Increased risk of scaffold thrombosis due to late discontinuity

**CENTRAL ILLUSTRATION** Potential Mechanisms in the Pathogenesis of Very Late Scaffold Thrombosis Scaffold Resorption Scaffold Implantation **Complete Resorption** Late Scaffold Discontinuity Scaffold Thrombosis Restenosis

Räber, L. et al. J Am Coll Cardiol. 2015; 66(17):1901-14.

Uneventful scaffold resorption results in positive remodeling with lumen expansion, intact intima, and normal vessel hemodynamics (upper right). In the presence of relevant areas of malapposed or uncovered scaffold struts, late scaffold discontinuity may cause dislocation of strut remnants into the lumen. This may lead to disturbed hemodynamic flow and activation of the thrombotic cascade potentially that result in very late scaffold thrombosis (lower left). Restenosis in the absence of relevant neointimal hyperplasia represents another potential mechanism in very late scaffold thrombosis (lower right).

#### **TCTAP2024**





# Background 1


- The polylactic acid (PLLA)-based bioabsorbable scaffold 'Absorb' has been commercially withdrawn from the market due to high scaffold thrombosis rates resulting from thick struts (150 μm) and long absorption periods (>3 years).
- To overcome these shortcomings of BRS, a novel sirolimus-eluting Mg alloybased bioabsorbable scaffolds (JFK-01) with thinner struts (110 μm) and shorter degradation rate (2.2 years) was investigated.



# Background 2

#### **Characteristics of JFK-01**

Material	Magnesium (free of rare earth metals)
Strut thickness	110 µm
Profiles width	1.2-1.3 mm
Percent of area in contact with vessel wall	17.4 %
Flexibility	5.46 mN <sup>-1</sup>
Initial strength	60-70 N/mm
Drug dose (3.0X20mm)	1.0 ug/mm <sup>2</sup>




2<sup>nd</sup>layer (PDLLA + Sirolimus) 1<sup>st</sup>layer (PLCL/PCL) Parylene C Fluoride-based layer RE-free Mg alloy

3.0x20mm




# Bioresorbable Mg alloy-based scaffold (JFK-01)







# Method of JFK-01 GLP Survival



### **Representative pictures of serial OCT images of JFK-01**




### **OCT** analysis








### Micro CT analysis of the implanted Mg scaffold






Percentage of degraded scaffold volume

#### **TCTAP2024**

CVRF

### **Representative histologic sections**




**JFK-01** 

**U-SES** 

**TCTAP2024** 


### **Pathological evaluation**



- Inflammation peaks at 180d in JFK-1 and decreased thereafter
- Calcification was observed but not extensive



## **Co-registration of histology, OCT, uCT, and SEM-EDX**




100 µm IMG1(frame1)

100 987

CVRF

CK

5 100 um



#### **TCTAP2024**



- OCT analysis demonstrated that there was no acute recoil, and the vascular patency was maintained throughout the study in all the scaffolds implanted.
- Vessel enlargement was observed at 15 M after scaffold implantation , and the trend was further augmented at 18, 24, and 26 M.
- Inflammation peaked at 18M and decreased thereafter.

- μCT, SEM-EDX, and histopathological analysis demonstrated that degradation of the Mg alloy backbone was confirmed at 6M with partial substitution of the Mg alloy strut by insoluble substances containing Ca and P.
- Further degradation with strut discontinuity was observed at 12M, and final replacement by carbon suggests complete resorption of the Mg alloy backbone at 26M.



# Progress of FIH testing of JFK-01

Scientific Title: An Exploratory Multicenter, Open-Label Clinical Study to Evaluate the Safety and Efficacy of JFK-01 (Coronary Artery Absorbable Magnesium Alloy Scaffold) in Patients with Ischemic Heart Disease

Contact for Scientific Queries /Name : Gaku Nakazawa

Affiliation : Kindai University Hospital

- > Anticipated date of first enrollment : Jan. 12, 2023
- Target sample size : 30

> Key inclusion & exclusion criteria /Inclusion Criteria:

- 1. De Novo Coronary Lesions
- 2. One lesion or two lesions in one or two branches that are eligible for PCI
- 3. Lesions with visual diameter stenosis (AHA stenosis classification) greater than 75% and less than 100%.
- 4. Lesions with TIMI classification grade 1 or higher blood flow

5. Lesions with a vessel diameter of 3 mm and lesion length of 18 mm or less

#### **TCTAP2024**

# Progress of FIH testing of JFK-01

FIH participating 10 facilities: Iwate Medical University Hospital, **Teikyo University Hospital Mitsui Memorial Hospital Tokai University Hospital Fujita Medical University Hospital Kindai University Hospital Kurashiki Central Hospital Kokura Memorial Hospital Kurume University Hospital Kumamoto University Hospital** > 17 cases included (202404)







In the current preclinical study, the novel bioresorbable drug eluting Mg alloy

scaffold system, JFK-01 demonstrated safety features with controlled

degradation of the Mg alloy backbone (2.2 years), resulting in long term

vessel enlargement with its complete resorption.

• First in Human trial is ongoing and enrollment will be completed Q4 2024.

